Synthesis, modeling, and biological evaluation of anti-tubulin indole-substituted furanones

Bioorg Med Chem Lett. 2023 Jun 15:90:129347. doi: 10.1016/j.bmcl.2023.129347. Epub 2023 May 24.

Abstract

Due to the central role of tubulin in various cellular functions, it is a validated target for anti-cancer therapeutics. However, many of the current tubulin inhibitors are derived from complex natural products and suffer from multidrug resistance, low solubility, toxicity issues, and/or the lack of multi-cancer efficacy. As such, there is a continued need for the discovery and development of new anti-tubulin drugs to enter the pipeline. Herein we report on a group of indole-substituted furanones that were prepared and tested for anti-cancer activity. Molecular docking studies showed positive correlations between favorable binding in the colchicine binding site (CBS) of tubulin and anti-proliferative activity, and the most potent compound was found to inhibit tubulin polymerization. These compounds represent a promising new structural motif in the search for small heterocyclic CBS cancer inhibitors.

Keywords: Antiproliferative; Antitubulin; Heterocyclic; Indole.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Binding Sites
  • Cell Line, Tumor
  • Cell Proliferation
  • Colchicine / chemistry
  • Drug Screening Assays, Antitumor
  • Indoles / chemistry
  • Molecular Docking Simulation
  • Structure-Activity Relationship
  • Tubulin Modulators / chemistry
  • Tubulin* / metabolism

Substances

  • Tubulin
  • Antineoplastic Agents
  • Tubulin Modulators
  • Colchicine
  • Indoles